Physician

Matthew C Dugan, D.O.

According to 2025 Medicare claims, Matthew Dugan, D.O. (NPI: 1386614295) practices medical oncology in the Portland-South Portland, ME market, with the plurality of this provider's patient population coming from Cumberland, ME. This provider's primary affiliated billing organization is MAINE CENTER FOR CANCER MEDICINE & BLOOD DISORDERS, P.A. (NPI: 1205896107; TIN: 010357684) and primary practice location at 04092-4877. Dugan is affiliated with the MaineHealth Accountable Care Organization (ACO ID: A1290), Aledade 201 National MSSP (ACO ID: A5522), and Beacon Rural Health, LLC (ACO ID: A5614), participating under the MSSP model.

Dugan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 354 traditional Medicare patients, billed 165,804 HCPCS/CPT codes, and received $3,493,254 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,174 prescription claims across 161 beneficiaries totaling $2,812,855 in drug costs, led by Tibsovo (Ivosidenib). DME data shows 68 claims. Open Payments data shows 62 records totaling $57,457. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,646,189 to $3,493,254. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,151,434 to $2,812,855. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $9,509 to $2,698.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	386	149,637	$1,646,189
2016	507	153,815	$2,129,772
2017	484	152,662	$2,663,100
2018	497	197,904	$3,524,383
2019	467	159,558	$3,249,933
2020	348	164,022	$3,073,792
2021	390	187,513	$3,823,159
2022	397	172,623	$3,349,766
2023	342	192,687	$3,850,811
2024	354	165,804	$3,493,254

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	148	948	$1,151,434
2016	156	1,082	$1,061,478
2017	152	930	$661,340
2018	169	1,008	$539,203
2019	181	1,032	$724,353
2020	164	954	$1,247,070
2021	160	1,064	$1,327,126
2022	153	1,028	$1,166,057
2023	162	1,059	$1,879,832
2024	161	1,174	$2,812,855

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	162	$24,431
2016	N/R	25	$1,793
2017	N/R	51	$4,403
2018	12	106	$6,791
2019	N/R	30	$1,104
2020	N/R	24	$1,860
2021	26	186	$11,594
2022	23	121	$4,727
2023	22	129	$15,838
2024	N/R	68	$38,561

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	123	452	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	144	292	$66
80053	Blood test, comprehensive group of blood chemicals	262	847	$10
36415	Insertion of needle into vein for collection of blood sample	246	625	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	286	888	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tibsovo	Ivosidenib	11	330	$322,538
Xalkori	Crizotinib	12	360	$293,024
Imbruvica	Ibrutinib	13	364	$213,145
Venclexta	Venetoclax	13	390	$162,706
Somatuline Depot	Lanreotide Acetate	14	392	$131,436

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J2354	Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg	N	N/R	13	$37,081
J8521	Capecitabine, oral, 500 mg	N	N/R	27	$972
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	28	$508

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	62	$57,457	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Matthew C. Dugan, D.O.?

Tedicare shows public-source Medicare data for Matthew C. Dugan, D.O. (NPI 1386614295), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Matthew C. Dugan, D.O. have ACO affiliation data?

Matthew C. Dugan, D.O. is shown with ACO affiliation data for MaineHealth Accountable Care Organization (MSSP, ACO ID A1290), Aledade 201 National MSSP (MSSP, ACO ID A5522), and Beacon Rural Health, LLC (MSSP, ACO ID A5614).

What billing organization is linked to Matthew C. Dugan, D.O.?

Matthew C. Dugan, D.O. is linked to MAINE CENTER FOR CANCER MEDICINE & BLOOD DISORDERS, P.A. (billing NPI 1205896107) in the available physician profile data.

Does Matthew C. Dugan, D.O. have Open Payments data?

Matthew C. Dugan, D.O. has 62 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.